EGFR/HER2-IN-7 is a highly selective and potent anticancer compound specifically designed to target MCF-7 breast cancer cells. It functions as a dual inhibitor, targeting both EGFR/HER2 kinases and DHFR (dihydrofolate reductase). Its inhibitory activities are measured with IC50 values of 0.18 μM for EGFR, 0.146 μM for HER2, and 0.907 μM for DHFR [1].

EGFR/HER2-IN-7 (compound 27) shows remarkable broad spectrum cytotoxic potency, with an IC 50 value of 10.81 μM against MCF-7 breast cancer cells [1]. EGFR/HER2-IN-7 (72 h) displays anti-breast cancer activity with an IC 50 value of 8.29 μM [1]. Cell Viability Assay [1] Cell Line: HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate and Hea cervical epithelioid carcinoma Concentration: 0-1 mM Incubation Time: 72 hours Result: Inhibited cancer cells growth with IC 50 s of 10.81 μM (HepG2), 8.29 μM (MCF-7), 13.78 μM (HCT-116), 16.63 μM (PC3), 7.63 μM (Hela), respectively. Cell Cytotoxicity Assay [1] Cell Line: Normal healthy cell line WI-38 (fetal lung fibroblast cells) Concentration: 0-1 mM Incubation Time: 72 hours Result: Showed low cytotoxicity against healthy cells with high IC 50 s of >100 μM, 67.2 μM, 54.18, 89.61 μM, 36.84 μM, 49.75 μM, respectively.